Skip to main content

Table 1 The clinical characteristics of enrolled patients with acute coronary syndromes

From: Prevalence and impact of fibrinolytic dysregulation in patients with acute coronary syndromes

Variable

Total

Fibrinolysis

P-value

Physiologic

Shutdown

Hyper-

n

338

99

163

76

Males, n(%)

272 (80.5)

84 (30.9)

134 (49.3)

54 (19.9)

0.055

Age, years

62.5 ± 12.8

62.6 ± 13.3

62.4 ± 13.1

62.5 ± 11.6

0.457

Smoking, n(%)

199 (58.9)

59 (59.6)

97 (59.5)

43 (56.6)

0.899

Hypertension, n(%)

150 (44.4)

41 (41.4)

70 (42.9)

39 (51.3)

0.373

Diabetes, n(%)

76 (22.5)

28 (28.3)

30 (18.4)

18 (23.7)

0.171

STEMI, n(%)

137 (40.5)

38 (38.4)

69 (42.3)

30 (39.5)

0.801

Stroke, n(%)

12 (3.6)

3 (3.0)

5 (3.1)

4 (5.3)

0.657

CKD, n(%)

22 (6.5)

9 (9.1)

8 (4.9)

5 (6.6)

0.412

CHF, n(%)

11 (3.2)

3 (3.0)

7 (4.3)

1 (1.3)

0.476

SBP, mmHg

134.5 ± 23.9

132.5 ± 25.8

134.3 ± 22.7

137.2 ± 23.9

0.202

Heart rate, beats/min

80.6 ± 16.5

81.0 ± 18.23

80.5 ± 16.1

80.4 ± 15.2

0.254

BMI, kg/m2

24.4 ± 3.5

24.0 ± 3.0

24.7 ± 3.9

24.1 ± 3.1

0.228

Troponin I, ng/ml

13.3 (0.94–60.0)

18.5 (1.3–66.8)

13.7 (1.6–74.2)

7.55 (0.33–52.0)

0.229

Serum Creatine, umol/L

87.9 (71.4–112.9)

87.9 (73.1–99.4)

86.3 (70.1–119.5)

90.1 (72.5–129.0)

0.036

ALT, U/L

31.2 (19.3–54.4)

31.2 (20.0–54.7)

31.8 (19.2–54.6)

29 (18.8–50.2)

0.762

Leukocytes, ×109/L

9.8 ± 3.7

9.6 ± 3.7

10.0 ± 3.9

9.4 ± 3.2

0.244

Hemoglobin, g/L

129.0 ± 22.5

130.9 ± 20.2

130.1 ± 23.5

124.2 ± 22.9

0.463

Platelets, ×109/L

217.7 ± 66.6

214.1 ± 69.3

214.9 ± 63.5

228.3 ± 69.1

0.637

Total cholesterol, mmol/L

4.8 ± 1.4

4.7 ± 1.2

4.7 ± 1.3

5.1 ± 1.9

0.026

D-dimers, ug/mL

0.47 (0.28–0.96)

0.48 (0.30–1.22)

0.47 (0.27–0.91)

0.43 (0.30–0.85)

0.790

Fibrinogen, g/L

3.97 ± 1.27

3.79 ± 1.00

4.06 ± 1.46

3.98 ± 1.13

0.041

APTT, sec

39.1 ± 12.8

39.1 ± 11.7

38.8 ± 9.9

39.6 ± 18.6

0.504

PT, sec

13.6 ± 3.4

13.2 ± 1.8

13.9 ± 4.5

13.4 ± 1.7

0.104

R-time, min

5.53 ± 2.79

5.13 ± 2.09

6.04 ± 3.46

4.98 ± 1.45

0.003

K-time, min

1.66 ± 1.00

1.54 ± 0.55

1.86 ± 1.31

1.38 ± 0.46

<0.001

Angle, degree

67.41 ± 8.90

68.32 ± 6.51

65.5 ± 10.7

70.28 ± 5.93

<0.001

MA, mm

64.37 ± 7.99

64.32 ± 6.12

64.67 ± 9.15

63.82 ± 7.51

0.082

LY30, %

0.8 (0–2.6)

1.6 (1.10–2.10)

0 (0–0.20)

5.05 (3.92–7.40)

0.001

ADP-IR, %

47.6 ± 32.8

45.7 ± 32.9

50.8 ± 33.1

43.4 ± 31.7

0.736

AA-IR, %

71.2 ± 28.9

66.6 ± 32.3

70.4 ± 28.3

78.4 ± 24.5

0.009

  1. Notes: STEMI ST-elevation myocardial infarction, CKD Chronic kidney diseases, CHF Congestive heart failure, SBP Systolic blood pressure, BMI Body mass index = weight (kg)/height(m)2, ALT Alanine aminotransferase, APTT Activated partial thromboplastin time, PT prothrombin time, MA Maximal amplitude, LY30 Lysis 30 min after MA, ADP-IR Adenosine diphosphate inhibition rate, AA-IR Arachidonic acid inhibition rate